Cambridge Healthtech Institute’s 5th Annual

Continuous Processing in Biopharm Manufacturing
( 連續製程 )

Improving Process Integration and Control

2019年8月12-13日


While the adoption rate for continuous bioprocessing has been slow, the industry is optimistic that continuous bioprocessing will happen once the initial challenges are resolved, and when current products are developed using such methods.

In upstream, perfusion technologies are becoming more popular with examples from many major biopharmaceutical companies. Downstream operations such as purification, however, have met with more barriers to adoption, particularly for clinical to GMP manufacturing.

Preliminary Agenda

MOVING FROM BATCH TO CONTINUOUS

Transformation to a New Intensified Process Platform

Jonathan Souquet, PhD, Head of GD&L Technology & Innovation, Merck Healthcare, Global Manufacturing & Supply, Merck Serono SA

An Integrated Bioprocess for Continuous Processing at FIH, Late Stage and Commercial

Ping Y. Huang, PhD, Director, Bioprocess Development, OED CMC BIologics, Abbvie

Taking Lessons from Small Molecule Continuous GMP Manufacturing

Ahmad Almaya, PhD, Director, Small Molecule Design and Development, Eli Lilly and Company

CONTINUOUS MANUFACTURING OF COMPLEX PROTEINS

Continuous Manufacturing in Microbials: Drawbacks and Possibilities

Christoph Slouka, PhD, PostDoc, Institute of Chemical, Environmental and Bioscience Engineering, TU Wien

Low-Cost, Highly Intensified Viral Vaccine Manufacturing

Alfred Luitjens, PhD, Director, Cell Technology, Batavia Biosciences

Challenges in Continuous Manufacturing of Exosomes

Agata Viliger-Oberbek, PhD, USP Head, Upstream Process Development, Codiak

CONTINUOUS VIRUS INACTIVATION AND CLEARANCE

Viral Clearance Validation Across Continuous Capture Chromatography (tentative title)

Srinivas Chollangi, PhD, Manager, Bristol-Myers Squibb

PAT AND ADVANCED PROCESS CONTROLS FOR CONTINUOUS MONITORING

CQAs Challenges and Impact on End-To-End Integrated Continuous Biomanufacturing

Robert Dream, Managing Director, HDR Company LLC

Advanced Process Controls Enabling Real-time Release Testing for Continuous Biomanufacturing (tentative title)

Udayanath Aich, PhD, Principal Scientist, Bioanalytics, Bristol-Myers Squibb


* 活動內容有可能不事先告知作更動及調整。